TRINETRA › Sectors › Healthcare
Piramal Pharma Limited (PPLPHARMA) — share price, P/E and fundamentals
Piramal Pharma Limited (NSE: PPLPHARMA) closed at ₹238.91 on 30 Oct 2026, +24.0% over one year, against a 52-week range of ₹132.30 – ₹240.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 27 Oct 2026) it reported revenue of ₹2,617 cr and net profit of ₹6 cr, a 0.2% net margin; revenue grew 28.1% year on year.
No trailing P/E is published: trailing twelve-month earnings are negative (-209 cr), so a P/E has no meaning — a loss-making business is not 'cheap' at a negative multiple. Judge it on revenue growth, cash burn and funding instead.
From the balance sheet dated 30 Sept 2026: return on equity 0.3%, ROCE 4.5%, debt-to-equity 0.70, Piotroski F-score 5 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 3% of 63 sector peers; PBT margin higher than 3% of 63 sector peers; ROE higher than 5% of 63 sector peers.
Key figures
| Last close | ₹238.91 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | +14.8% / +44.4% / +24.0% |
| 52-week low – high | ₹132.30 – ₹240.00 |
| Market capitalisation | ₹31,737 cr |
| Price / book | 3.90 |
| EV / EBITDA | 30.8 |
| TTM EPS | ₹-1.57 |
| TTM net profit | ₹-209 cr |
| Quarter revenue | ₹2,617 cr |
| Quarter net profit | ₹6 cr |
| Net margin | 0.2% |
| Revenue growth (YoY) | +28.1% |
| Return on equity | 0.3% |
| ROCE | 4.5% |
| Debt / equity | 0.70 |
| Current ratio | 1.41 |
| Free cash flow | ₹-468 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹58.8 cr |
Against Healthcare peers
| Metric | PPLPHARMA | Peer median | Percentile |
|---|---|---|---|
| Net margin | 0.21 | 12.89 | 3 |
| PBT margin | 2.44 | 17.68 | 3 |
| ROE | 0.27 | 13.87 | 5 |
| ROCE | 4.53 | 17.26 | 10 |
| Debt / equity | 0.70 | 0.11 | 95 |
| FCF margin | -9.57 | 2.08 | 14 |
| P/B | 3.90 | 6.02 | 20 |
| EV/EBITDA | 30.77 | 22.34 | 72 |
Questions
What were Piramal Pharma Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Piramal Pharma Limited reported revenue of ₹2,617 cr and net profit of ₹6 cr (consolidated), filed with the exchange on 27 Oct 2026.
What is Piramal Pharma Limited's ROE?
Return on equity is 0.3% based on the balance sheet dated 30 Sept 2026.
Does Piramal Pharma Limited have debt?
Debt-to-equity is 0.70 on the balance sheet dated 30 Sept 2026.
What is PPLPHARMA's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, PPLPHARMA traded between ₹132.30 and ₹240.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.